Alberto Castro

28 posts

Alberto Castro banner
Alberto Castro

Alberto Castro

@acastrom91

•Cardiology Research Fellow-Harvard/BIDMC | •MD Universidad Autónoma de Guadalajara | •Director of the WikiDoc Scholar Progam

Boston, MA Katılım Şubat 2022
130 Takip Edilen47 Takipçiler
Alberto Castro retweetledi
C. Michael Gibson MD
C. Michael Gibson MD@CMichaelGibson·
20 years ago over New Years, I founded WikiDoc.org , a free, copyleft, open access textbook of medicine. Thousands of doctors have edited it millions of times. It is viewed over a billion times per year. Send an email to alberto.castro@baiminstitute.org to become an editor and help keep our content up to date and earn academic credit !
C. Michael Gibson MD tweet media
English
8
120
511
35.5K
Alberto Castro
Alberto Castro@acastrom91·
Another @wikidoc meeting where the dissemination of medical knowledge and global collaboration come together to build a true academic community. Honored to be part of a project founded by my mentor Dr. @CMichaelGibson that continues to impact medical education worldwide #MedEd
Alberto Castro tweet media
English
1
5
17
4K
Alberto Castro retweetledi
Internal Medicine Interest Group - Journal Club
As co-founders of the Internal Medicine Interest Group (IMIG), we are proud to present a platform dedicated to discussion, engagement, and enrichment of those who wish to be part of it.
Internal Medicine Interest Group - Journal Club tweet media
English
1
2
6
434
Alberto Castro retweetledi
JACC Journals
JACC Journals@JACCJournals·
#ACC24 #JACC LBCT SimPub: #AEGIS-II trial shows numerically lower rates of CV death & #cvMI, type-1 MI, & stent thrombosis-related MI compared to placebo suggesting a role of apoA-I in ⬇️ subsequent plaque disruption events via enhanced cholesterol efflux bit.ly/3PSxU9M
JACC Journals tweet media
English
5
18
35
13.8K
Alberto Castro retweetledi
C. Michael Gibson MD
C. Michael Gibson MD@CMichaelGibson·
AEGIS-II trial shows in AMI pts with multivessel disease + additional CV risk factors and on GDMT, 4 weekly infusions of CSL112 did not reduce primary endpoint of CV death, MI, or stroke thru 90 days. Additional analysis shows CV outcome benefits statistically significant in pts with baseline high LDL > 100 mg/dl.
C. Michael Gibson MD tweet mediaC. Michael Gibson MD tweet mediaC. Michael Gibson MD tweet mediaC. Michael Gibson MD tweet media
English
6
36
112
12.3K
Alberto Castro retweetledi
ACC Media Center
ACC Media Center@ACCmediacenter·
If your LDL is low & you don’t have a lot of lipid in your plaque then delipidation is not going to help. If you have high LDL, you have more lipid in your plaque and should have the garbage trucks take the garbage out, summarizes Dr. @CMichaelGibson on the AEGIS-II trial. #ACC24
ACC Media Center tweet media
English
1
15
47
4.9K
Alberto Castro retweetledi
C. Michael Gibson MD
C. Michael Gibson MD@CMichaelGibson·
In todays Wall Street Journal I talk about how new anticoagulant drugs called Factor XI inhibitors could reduce the higher risk of bleeding: “Too low of a dose, you clot; too high of a dose, you bleed. Our goal is to keep people from falling off the balance beam.” wsj.com/health/pharma/… via @WSJ
English
2
9
34
7K
Alberto Castro retweetledi
C. Michael Gibson MD
C. Michael Gibson MD@CMichaelGibson·
RIGHT trial: Routine post-procedural anticoagulation after primary PCI in STEMI fails to improve ischemic outcomes at 30 days #ESCCongress
C. Michael Gibson MD tweet media
English
2
21
71
13.8K